GUT Vitamin B12 supplements may help treat hepatitis C
Published Online First 17 July 2012
Download PDF
Safe and inexpensive option for boosting response rate to antiviral drugs [Vitamin B12 supplementation improves the rate of sustained viral response in patients chronically infected with hepatitis C virus
Online First doi 10.1136/gutjnl-2012-302344]
Adding vitamin B12 to standard hepatitis C virus (HCV) treatment significantly boosts the body’s ability to keep the virus at bay, indicates a pilot study published online in the journal Gut.
The effects were particularly strong in patients whose infection was proving difficult to treat effectively, the findings showed. Between 60% and 80% of those infected with the viral liver infection HCV will go on to develop chronic hepatitis, and roughly
a third of them will progress to cirrhosis and terminal liver disease.
Standard treatment of interferon (peg IFN) and ribavarin clears the virus in about 50% of patients infected with genotype 1 HCV and 80% of those infected with genotypes 2 or 3. But this approach fails to clear the virus in around half of all those infected with HCV or the infection returns once treatment stops.
While trials of new generation antiviral drugs show promise, they are expensive, and can make treatment more difficult. And
questions still remain about how well they will work in practice, say the authors.
Experimental research dating back a decade suggests that vitamin B12 may have a role in suppressing HCV.
The liver is the body’s primary storage centre for vitamin B12, but this capacity is impaired by diseases directly affecting the organ. The researchers therefore wanted to see if adding vitamin B12 to standard treatment would make a difference.
Ninety four patients with HCV infection were randomly allocated to receive standard treatment or standard treatment plus vitamin B12 (5000 ug every 4 weeks) for between 24 (genotypes 2 and 3) and 48 weeks (genotype 1).
The body’s ability to clear the virus was assessed after 4 weeks (rapid viral response), after 12 weeks (complete early viral response), at the end of treatment and at 24 weeks after stopping treatment (sustained viral response).
There was no difference between the two treatment approaches at 4 weeks, but there were significant differences in response at all the other time points, particularly 24 weeks after stopping treatment, which is the aim of HCV treatment and the closest it can be get to a cure.
The effects were also significantly greater among those who carried the type 1 strain, which is particularly hard to treat, and those high levels of infection (high viral load) to begin with.
Overall, adding vitamin B12 to standard therapy strengthened the rate of sustained viral response by 34%, the findings showed.
The authors conclude that until clear eligibility criteria for treatment with the new generation antiviral drugs are established, standard treatment plus vitamin B12 is a safe and inexpensive alternative, particularly for those who carry a strain of the virus that is hard to treat.
They add: “This strategy would be especially useful in those countries where, owing to limited economic means, the new generation antiviral therapies cannot be given in routine practice.”
Gut doi:10.1136/gutjnl-2012-302344
- Hepatology
- Original article
Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus
1.Alba Rocco1, 2.Debora Compare1, 3.Pietro Coccoli1, 4.Ciro Esposito2, 5.Antimo Di Spirito2, 6.Antonio Barbato3, 7.Pasquale Strazzullo3, 8.Gerardo Nardone1
+ Author Affiliations 1. 1Department of Clinical and Experimental Medicine, Gastroenterology Unit, University of Naples “Federico II”, Naples, Italy 2. 2Unit of Virology, “D. Cotugno” Hospital, Naples, Italy 3. 3Internal Medicine Unit, University of Naples “Federico II”, Naples, Italy
1.Correspondence to Professor Gerardo Nardone, Department of Clinical and Experimental Medicine, Gastroenterology Unit, University of Naples “Federico II”, via Pansini 5, 80131 Naples, Italy; nardone@unina.it
1. Contributors AR, DC, GN: study concept and design and drafting of the manuscript. AR, DC, PC, CE, ADS: acquisition of data. AR, AB: analysis and interpretation of data; statistical analysis. PS, GN: critical revision of the manuscript for important
intellectual content.
•Revised 5 June 2012 •Accepted 6 June 2012
•Published Online First 17 July 2012
Abstract
Background In vitro, vitamin B12 acts as a natural inhibitor of hepatitis C virus (HCV)
replication.
Objective To assess the effect of vitamin B12 on virological response in patients with chronic HCV hepatitis naïve to antiviral therapy.
Methods Ninety-four patients with chronic HCV hepatitis were randomly assigned to receive pegylated interferon α plus
ribavirin (standard-of-care; SOC) or SOC plus vitamin B12 (SOC+B12). Viral response—namely, undetectable serum HCV-RNA, was evaluated 4 weeks after starting treatment (rapid viral response),
12 weeks after starting treatment (complete early viral response) and 24 or 48 weeks after starting treatment (end-of-treatment viral response) and 24 weeks after completing treatment (sustained viral response (SVR)). Genotyping for the interleukin (IL)-28B polymorphism was performed a posteriori in a subset (42/64) of HCV genotype 1 carriers.
Results Overall, rapid viral response did not differ between the two groups, whereas the rates of complete early viral
response (p=0.03), end-of-treatment viral response (p=0.03) and SVR (p=0.001) were significantly higher in SOC+B12 patients than in SOC patients. In SOC+B12 patients, the SVR rate was also significantly higher in carriers of a
difficult-to-treat genotype (p=0.002) and in patients with a high baseline viral load (p=0.002). Distribution of genotype
IL-28B did not differ between the two groups. At multivariate analysis, only easy-to-treat HCV genotypes (OR=9.00; 95% CI 2.5 to 37.5; p=0.001) and vitamin B12 supplementation (OR=6.9; 95% CI 2.0 to 23.6; p=0.002) were independently
associated with SVR.
Conclusion Vitamin B12 supplementation significantly improves SVR rates in HCV-infected patients naïve to antiviral therapy.
http://gut.bmj.com/content/early/2012/06/28/gutjnl-2012-302344